サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Global Antiretroviral Drugs Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors), By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, South Africa)

世界の抗レトロウイルス薬市場:薬剤タイプ別(マルチクラス薬剤併用、NRTI、NNRTI、プロテアーゼ阻害薬)、地域別、国別分析(2019年度版):ビジネスチャンスと予測(2013〜2023年)

レポート概要

本レポートは、広範なプライマリー調査(業界専門家、企業、出資者からの情報)やセカンダリー調査を通して作成され、薬剤タイプ別(マルチクラス薬剤併用、NRTI、NNRTI、プロテアーゼ阻害薬)、地域別(北米、欧州、APAC、その他)、および国別(米国、カナダ、ドイツ、イギリス、フランス、イタリア、インド、日本、中国、南アフリカ)の分析を元に、世界の抗レトロウイルス薬市場を調査しました。また、一部の抗レトロウイルス薬の売上も含みます。

世界の抗レトロウイルス薬市場は、2018~2023年にかけて、CAGR 4.7%で勢い良く成長する見込みです。

近年、抗レトロウイルス薬市場は、HIV/エイズの有病率の増加、抗レトロウイルス治療の普及率の向上、およびより有効性の高い新薬の入手可能性の増加など、いくつかの要因によって成長を目の当たりにしています。さらに、医療費の増加、各国政府による有利な措置、治療費の削減、診断率の向上、および未治療患者集団に診断および治療を提供するための有利なプログラムの増加などの要因が、市場の成長を牽引してきました。さらに、INSTIベースのレジメンの普及、HIV治療と治療手順に関する意識の高まり、新薬の上市、そして研究開発パイプラインの改善が、予測期間中の市場成長を後押しすると予想されます。ただし、ジェネリック抗レトロウイルス薬のポートフォリオの拡大は、市場全体の成長に影響を与えると予想されます。

本レポートでは、市場は薬の種類に基づいて分割されています。薬剤の種類別に見ると、マルチクラス薬剤併用が市場での主導的地位を維持すると予測されています。特にGilead Sciences社のBiktarvyとViiV Healthcare社のTriumeqが市場に一層の注目を集めると予想されます。地域の中では、北米は2017年に世界の抗レトロウイルス市場で最大の地域シェアを占めました。北米の最大のシェアは、高いART適応率とブランド処方薬にもっと重点を置いていることに起因しています。

本レポートは、世界の抗レトロウイルス薬市場の潜在性について分析し、市場規模、シェア、成長要因についての統計や情報を提供します。また、最先端の市場戦略情報を提供し、意思決定者が健全な投資の評価を行うのに役立ちます。さらに、主な市場促進要因、課題、ビジネスチャンス、様々な企業の市場参入戦略についても取り上げます。

■調査範囲

世界市場分析(実データ:2013~2017年、予測期間:2018~2023年)

  • 世界の抗レトロウイルス薬市場‐規模、成長、予測
  • 薬剤タイプ別(マルチクラス薬剤併用、NRTI、NNRTI、プロテアーゼ阻害薬)
  • 薬剤売上予測
    ➣ マルチクラス薬剤併用:Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®
    ➣ ヌクレオシド系逆転写酵素阻害薬:Epzicom®/ Kivexa®
    ➣ 非ヌクレオシド系逆転写酵素阻害薬:Edurant®
    ➣ プロテアーゼ阻害薬:PREZISTA ® /PREZCOBIX® /REZOLSTA ®
    ➣ インテグラーゼ鎖転移阻害薬:Tivicay®, Isentress/Isentress HD®
    ➣ CCR5阻害薬:Selzentry®/ Celsentri®

地域市場分析‐北米、欧州、アジア太平洋、その他(実データ:2013~2017年、予測期間:2018~2023年)
世界市場分析(実データ:2013~2017年、予測期間:2018~2023年)

  • 抗レトロウイルス薬市場‐規模、成長、予測
  • 薬剤タイプ別(マルチクラス薬剤併用、NRTI、NNRTI、プロテアーゼ阻害薬)

国別分析‐米国、カナダ、ドイツ、イギリス、フランス、イタリア、インド、日本、中国、南アフリカ(実データ:2013~2017年、予測期間:2018~2023年)
世界市場分析(実データ:2013~2017年、予測期間:2018~2023年)

  • 抗レトロウイルス薬市場‐規模、成長、予測
  • 薬剤タイプ別(マルチクラス薬剤併用、NRTI、NNRTI、プロテアーゼ阻害薬)

その他

  • 製品売上予測
  • 市場ダイナミクス‐促進要因、抑制要因
  • 市場動向
  • SWOT分析
  • ポーターファイブフォース分析
  • 企業分析‐Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan

レポート詳細

目次

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Antiretroviral Drugs Products Outlook

5. Global Antiretroviral Drugs Market: Growth and Forecast
5.1 By Value (2013-2017)
5.2 By Value (2018-2023)

6. Global Antiretroviral Drugs Market: Segment Analysis
6.1 Global Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
6.1.1 Global Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
6.1.2 Global Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
6.2 Global Multi-Class Drugs Combination Market Size, By Value (2013-2023)
6.3 Global NRTI Market Size, By Value (2013-2023)
6.4 Global NNRTI Market Size, By Value (2013-2023)
6.5 Global Protease Inhibitors Market Size, By Value (2013-2023)
6.6 Global Other Antiretroviral Drugs Market Size, By Value (2013-2023)
6.6 Global Antiretroviral Drugs: Market Attractiveness, By Drug Type
6.7 Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5)

7. Global Antiretroviral Drugs Market: Regional Analysis
7.1 Global Antiretroviral Drugs Market Size, By Region : Breakdown (%)
7.1.1 Global Antiretroviral Drugs Market Size, By Region, 2017 (%)
7.1.2 Global Antiretroviral Drugs Market Size, By Region, 2023 (%)

8. North America Antiretroviral Drugs Market: Growth and Forecast
8.1 North America Antiretroviral Drugs Market: Segmental Analysis
8.2 North America Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
8.2.1 North America Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
8.2.2 North America Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
8.3 North America Multi-Class Drugs Combination Market Size, By Value (2013-2023)
8.4 North America NRTI Market Size, By Value (2013-2023)
8.5 North America NNRTI Market Size, By Value (2013-2023)
8.6 North America Protease Inhibitors Market Size, By Value (2013-2023)
8.7 North America Other Antiretroviral Drugs Market Size, By Value (2013-2023)

8.9 North America Antiretroviral Drugs Market: Country Analysis (U.S and Canada)
8.9.1 U.S Antiretroviral Drugs Market, By Value (2013-2023)
8.9.2 U.S Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

8.9.3 Canada Antiretroviral Drugs Market, By Value (2013-2023)
8.9.4 Canada Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9. Europe Antiretroviral Drugs Market: Growth and Forecast
9.1 Europe Antiretroviral Drugs Market: Segmental Analysis
9.2 Europe Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
9.1.2 Europe Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
9.1.3 Europe Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
9.3 Europe Multi-Class Drugs Combination Market Size, By Value (2013-2023)
9.4 Europe NRTI Market Size, By Value (2013-2023)
9.5 Europe NNRTI Market Size, By Value (2013-2023)
9.6 Europe Protease Inhibitors Market Size, By Value (2013-2023)
9.7 Europe Other Antiretroviral Drugs Market Size, By Value (2013-2023)

9.8 Europe Antiretroviral Drugs Market: Country Analysis (Germany, France, U.K, Italy)

9.8.1 Germany Antiretroviral Drugs Market, By Value (2013-2023)
9.8.2 Germany Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.4 France Antiretroviral Drugs Market, By Value (2013-2023)
9.8.5 France Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.6 UK Antiretroviral Drugs Market, By Value (2013-2023)
9.8.7 UK Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9.8.8 Italy Antiretroviral Drugs Market, By Value (2013-2023)
9.8.9 Italy Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10. APAC Antiretroviral Drugs Market: Growth and Forecast

10.1 APAC Antiretroviral Drugs Market: Segmental Analysis
10.2 APAC Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
10.2.1 APAC Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
10.2.2 APAC Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
10.3 APAC Multi-Class Drugs Combination Market Size, By Value (2013-2023)
10.4 APAC NRTI Market Size, By Value (2013-2023)
10.5 APAC NNRTI Market Size, By Value (2013-2023)
10.6 APAC Protease Inhibitors Market Size, By Value (2013-2023)
10.7 APAC Other Antiretroviral Drugs Market Size, By Value (2013-2023)

10.8 APAC Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
10.8.1 China Antiretroviral Drugs Market, By Value (2013-2023)
10.8.2 China Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10.8.3 Japan Antiretroviral Drugs Market, By Value (2013-2023)
10.8.4 Japan Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10.8.5 India Antiretroviral Drugs Market, By Value (2013-2023)
10.8.6 India Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

11. ROW Antiretroviral Drugs Market: Growth and Forecast
11.1 ROW Antiretroviral Drugs Market: Segment Analysis
11.2 ROW Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
11.1.1 ROW Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
11.1.2 ROW Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
11.3 ROW Multi-Class Drugs Combination Market Size, By Value (2013-2023)
11.4 ROW NRTI Market Size, By Value (2013-2023)
11.5 ROW NNRTI Market Size, By Value (2013-2023)
11.6 ROW Protease Inhibitors Market Size, By Value (2013-2023)
11.7 ROW Other Antiretroviral Drugs Market Size, By Value (2013-2023)

11.8 ROW Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
11.8.1 South Africa Antiretroviral Drugs Market, By Value (2013-2023)
11.8.2 South Africa Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

12. Global Antiretroviral Drugs Market: Market Dynamics
12.1 Global Antiretroviral Drugs Market: Drivers
12.2 Global Antiretroviral Drugs Market: Restrains
12.3 Global Antiretroviral Drugs Market: Trends
12.4 Global Antiretroviral Drugs Market: Product Benchmarking

13. Porter Five Force Analysis

14. SWOT Analysis

15. Company Profiles
15.1 Gilead Sciences
15.2 ViiV Healthcare
15.3 Bristol-Myer Squibb
15.4 AbbVie Inc.
15.5 Boehringer-Ingelheim
15.6 Johnson and Johnson
15.7 Merck & Co.
15.8 CIPLA
17.9 Merck & Co,

Figure 1: Global Antiretroviral Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 2: Global HIV, AIDS Prevalence, 2013-2017, Millions
Figure 3: Global HIV Prevalence, By Population Group, 2017
Figure 4: Global HIV Prevalence By Region, 2017
Figure 5: Change in the HIV Infection Prevalence in Between 2010 & 2017
Figure 6: Global HIV Treatment Status, 2017
Figure 7: HIV Patients on ARV Treatment, 2013-2017 (% of Total Patients)
Figure 8: Comparison on Number of HIV with Number of Patients on ART, 2013-2017, (Million)
Figure 9: HIV Related Deaths, 2013-2017, (Million)
Figure 10: INSTI Based Regimen, 2018 ( USD Million)
Figure 11: harmaceutical Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
Figure 12: HIV Funding In Low and Middle Income Countries, 2013-2017, (USD Billions)
Figure 13: PEPFAR Funding, 2015-2017 (USD Millions)
Figure 14: HIV Prevalence Region Wise, 2017 (Millions)
Figure 15: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
Figure 16: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 17: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 18: Global Aged Population(Above 65), By Country, 2017 (% of total)
Figure 19: Global Aged Population (Above 65), 2013-2017 (% of total)
Figure 20: HIV DAYLs Per 100000, Global, All Sex, All Age, 2013-2017
Figure 21: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
Figure 22: Global Expected Healthcare Industry Outlook
Figure 23: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 24: Global Antiretroviral Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 25: Global Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 26: Global Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 27: Global Multi-Class Drugs Combination Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 28: Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2018-2023(USD Million)
Figure 29: Global NRTI Antiretroviral Drugs Drugs Market, By Value, 2013-2017 (USD Million)
Figure 30: Global NRTI Antiretroviral Drugs Drugs Market, 2018-2023(USD Million)
Figure 31: Global NNRTI Antiretroviral Drugs Drugs Market, By Value, 2013-2017 (USD Million)
Figure 32: Global NNRTI Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 33: Global Protease Inhibitors Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 34: Global Protease Inhibitors Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 35: Global Other Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 36: Global Other Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 37: Global Market Attractiveness, By Product Type, 2023F
Figure 38: Stribild®, Sales, 2013-2023F, (USD Million)
Figure 39: Triumeq®, Sales, 2014-2023F , (USD Million)
Figure 40: Genvoya®, Sales, 2016-2023F, (USD Million)
Figure 41: Odefsey®, 2016-2023F, (USD Million)
Figure 42: Juluca®, Sales, 2017-2023F, (USD Million)
Figure 43: Biktarvy®, Sales, 2018-2023F, (USD Million)
Figure 44: Epzicom/ Kivexa®, Sales, 2013-2023F, (USD Million)
Figure 45: EDURANT®, Sales, 2013-2023F, (USD Million)
Figure 46: PREZISTA/PREZCOBIX® /REZOLSTA®, Sales, 2013-2023F, (USD Million)
Figure 47: Tivicay®, Sales, 2013-2023F, (USD Million)
Figure 48: Isentress/Isentress HD 2013-2023F, (USD Million)
Figure 49: Selzentry® / Celsentri®2013-2023F, (USD Million)
Figure 50: Global Antiretroviral Drugs Market Size, By Region, 2017 (%)
Figure 51: Global Antiretroviral Drugs Market Size, By Region, 2023F (%)
Figure 52: North America Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 53: North America, HIV Prevalence, 2013-2017
Figure 54: North America HIV Incidence vs HIV Related Deaths,2013-2017
Figure 55: United States Spending on Medicines, 2013-2017 (In USD Billion)
Figure 56: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
Figure 57: North America population aged 65 and above, 2013-2017 (% of total)
Figure 58: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 59: North America GDP per Capita, 2013-2017 (USD)
Figure 60: North America Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
Figure 61: North America Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 62: North America Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 63: North America Antiretroviral Drugs Market,By Drug Type, By Value, 2013-2017 (USD Million)
Figure 64: North America Antiretroviral Drugs Market,By Drug Type , By Value, 2018-2023(USD Million)
Figure 65: North America Antiretroviral Drugs Market Size, By Countries, 2017 (%)
Figure 66: North America Antiretroviral Drugs Market Size, By Countries, 2023F (%)
Figure 67: USA Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 68: USA Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 69: HIV Prevalence, USA, 2013-2017, (Millions)
Figure 70: New HIV Cases, By Age, USA, 2017
Figure 71: HIV Prevalence, USA, By Ethnicity, 2016
Figure 72: New HIV Cases, By States, USA, 2017
Figure 73: HIV Related Statistics, USA, 2017
Figure 74: HIV Funding, USA, 2017, USD Billion
Figure 75: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 76: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
Figure 77: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
Figure 78: U.S., Population ages 65 and above, 2013-2017 (% of total)
Figure 79: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 80: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 81: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Figure 82: USA Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 83: USA Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 84: USA Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 85: USA Antiretroviral Drugs Market,By Drug Type, By Value, 2018-2023(USD Million)
Figure 86: Canada Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 87: Canada Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 88: Canada HIV Prevalence, 2013-2017
Figure 89: Canada, HIV Related Statistics, 2017
Figure 90: Canada, HIV Prevalence By Sex & Ethnicity
Figure 91: Number of Retail Pharmacies in Canada, 2013-2017
Figure 92: Number of Hospitals Establishments in Canada, By Province, 2015
Figure 93: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Figure 94: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 95: Canada, Population ages 65 and above, 2012-2017 (% of total)
Figure 96: anada Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 97: Canada Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 98: Canada Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 99: Europe Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 100: Europe, HIV Prevalence, 2013-2017
Figure 101: European Union, Antiretroviral Drugs Therapy Coverage, 2013-2017, (% of Total Patient Population)
Figure 102: Percentage of new HIV diagnoses, By country and Sge group, EU/EEA, 2017
Figure 103: Proportion of New HIV Diagnoses, By Country and transmission, EU/EEA, 2017
Figure 104: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
Figure 105: Europe Population ages 65 years and above (% of total population), 2013-17
Figure 106: Europe Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
Figure 107: Europe Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 108: Europe Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 109: Europe Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 110: Europe Antiretroviral Drugs Market Size, By Countries, 2017 (%)
Figure 111: Europe Antiretroviral Drugs Market Size, By Countries, 2023F (%)
Figure 112: Germany Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 113: Germany Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 114: Germany, HIV Prevalence, 2013-2017
Figure 115: Germany, ARV Coverage, (% of Total Patients)
Figure 116: Germany, Healthcare Related Statistics, 2017
Figure 117: Germany, Population ages 65 and above, 2012-2017 (% total)
Figure 118: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 119: Germany Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 120: Germany Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 121: Germany Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 122: France Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 123: France Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 124: France, HIV Prevalence, 2013-2017
Figure 125: France, HIV Prevalence, 2017, By Sex, (% of Total)
Figure 126: France, Healthcare Infrastructure Related Statistics
Figure 127: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter),
Figure 128: France, ART Coverage, 2013-2017, (% of Total Patients)
Figure 129: France, ART Coverage, % of Total, By Sex, 2017
Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017
Figure 131: France, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 132: France Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 133: France Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 134: France Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 135: U.K Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 136: U.K Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 137: U.K, HIV Prevalence, 2013-2017
Figure 138: UK, HIV Treatment Status, 2017
Figure 139: UK, HIV Related Statistics, 2017
Figure 140: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 141: U.K, Population Ages 65 and Above (% of total), 2012-2017
Figure 142: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 143: U.K Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 144: U.K Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 145: U.K Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 146: Italy Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 147: Italy Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 148: Italy, HIV Prevalence, 2013-2017
Figure 149: Italy, ART Coverage, 2013-2017
Figure 150: Italy, AIDS Prevalence, By Age, 2017
Figure 151: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 152: Italy, Population Ages 65 and Above (% of total), 2012-2017
Figure 153: Italy, Healthcare Infrastructure Related Statistics
Figure 154: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 155: Italy Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 156: Italy Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 157: Italy Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 158: APAC Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 159: Indonesia, HIV Prevalence, 2013-2017
Figure 160: APAC, HIV Prevalence, By Selected Countries, 2017
Figure 161: APAC, HIV Treatment Status, 2017
Figure 162: APAC, Incidence vs Death Ratio, By Selected Countries,2017
Figure 163: China, Pharmaceuticals Industry Revenue (USD Billion)
Figure 164: Japan, Total Drugs Market, 2013-2017, USD Billion
Figure 165: India Pharma Market, 2015-2017, (USD Billion)
Figure 166: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
Figure 167: Population ages 65 and above, By Select Country, 2017 (% of total)
Figure 168: APAC Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
Figure 169: APAC Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 170: APAC Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 171: APAC Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 172: APAC Antiretroviral Drugs Market Size, By Countries, 2017 (%)
Figure 173: APAC Antiretroviral Drugs Market Size, By Countries, 2023F (%)
Figure 174: China Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 175: China Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 176: China, HIV Prevalence, 2013-2017
Figure 177: China, HIV Related Deaths, 2013-2016
Figure 178: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 179: China, Share of Urban Population, 2012-2017 (In %)
Figure 180: China, Total Population, 2013-2021F (In Billion)
Figure 181: China Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 182: China Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 183: China Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 184: Japan Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 185: Japan Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 186: Japan Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 187: Japan, HIV Prevalence, 2013-2017
Figure 188: Japan, Medical & HIV Facilities Outlook
Figure 189: Japan Healthcare Expenditure Outlook (%)
Figure 190: Japan, HIV DALYs Rate, (Per 100000), 2013- 2017
Figure 191: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 192: Japan Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 193: Japan Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 194: Japan Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 195: India Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 196: India Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 197: India, HIV Prevalence, 2013-2017
Figure 198: India, ART Coverage, (% of Patient Population)
Figure 199: India, HIV Treatment Status, 2017
Figure 200: India, Diseases & Medical Industry Outlook
Figure 201: India, Population ages 65 and above, 2013-2017
Figure 202: India, Total Population, 2013-2023F (In Billion)
Figure 203: Pharma Export From India Market, 2013-2017, (USD Billion)
Figure 204: India Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 205: India Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 206: India Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 207: ROW Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 208: ROW, HIV Prevalence, By Country, 2013-2017
Figure 209: ROW, ART Coverage, 2013-2017, (% of Total Patient Population), By Selected Countries
Figure 210: ROW, HIV DALYs, Rate Per 100000 Population, By Selected Countries, 2017
Figure 211: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 212: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
Figure 213: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 214: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
Figure 215: ROW Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
Figure 216: ROW Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
Figure 217: ROW Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 218: ROW Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 219: South Africa Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
Figure 220: South Africa Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
Figure 221: South Africa, HIV Prevalence, 2013-2017
Figure 222: South Africa, HIV Prevalence, By Age, 2013-2017
Figure 223: South Africa, ART Coverage, 2013-2017, (% of Total)
Figure 224: South Africa, HIV Treatment Status, 2017
Figure 225: South Africa, Comparison Between Patients on ART and HIV Deaths, 2013-2017
Figure 226: South Africa, DALYs, (% of Life Years)
Figure 227: South Africa Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
Figure 228: South Africa Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
Figure 229: South Africa Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
Figure 230: Gilead Sciences Inc., Net Sales, 2013-2017 (USD Million)
Figure 231: Gilead Sciences Inc., By Segments, 2017(%)
Figure 232: Gilead Sciences Inc., By Region, 2017(%)
Figure 233: Gilead Sciences Inc., ARV Drugs Patent Status, United States and Europe
Figure 234: GSK (ViiV Healthcare), Net HIV Drugs Sales, 2013-2017 (USD Million)
Figure 235: GSK (ViiV Healthcare), HIV Drugs Sales, By Drugs, 2017 (USD Million)
Figure 236: GSK (ViiV Healthcare), HIV Drugs Sales, By Geographic Region, (% of Total), 2017
Figure 237: GSK (ViiV Healthcare), HIV Drugs, Patent Status
Figure 238: Bristol-Myers Squibb, Net Sales, 2013-2017 (USD Million)
Figure 239: Bristol-Myers Squibb, By Region, 2017(%)
Figure 240: Bristol-Myers Squibb, Net Sales, By Segments, 2017 (USD Million)
Figure 241: AbbVie Inc., Net Sales, 2013-2017 (USD Million)
Figure 242: AbbVie Inc., Sales, By Region, 2017(%)
Figure 243: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million)
Figure 244: Boehringer-Ingelheim, By Segments, 2017(%)
Figure 245: Boehringer-Ingelheim, By Region, 2017(%)
Figure 246: Johnson & Johnson Pharmaceuticals, Net Sales, 2013-2017 (USD Million)
Figure 247: Johnson & Johnson Pharmaceuticals, ARV Drug Sales, 2015-2017 (USD Million)
Figure 248: Johnson & Johnson Pharmaceuticals, By Segments, 2017(%)
Figure 249: Johnson & Johnson Pharmaceuticals, By Region, 2017(%)
Figure 250: Merck & Co., Revenues 2013-2017(USD Million)
Figure 251: Merck & Co., Revenues, By Region, 2017(% of Total)
Figure 252: Merck & Co., Isentress Sales, 2015-2017(USD Million)
Figure 253: Cipla, Net Sales, 2013-2017 (USD Million)
Figure 254: Cipla, Sales, By Region, 2017(%)
Figure 255: Mylan, Net Sales, 2013-2017 (USD Million)
Figure 256: Mylan, By Region, 2017(%)

Table A: Different Types of Antiretroviral Drugs Drugs
Table B: ARV Regimen Priority Wise Recommendation in US and Europe, 2018
Table C: ARV Drugs in Development Phase
Table D: ARV Drugs Patent Status
Table E: Major ARV Drugs Brands, By Class
Table F: Product Benchmarking

発刊日

2019/03/31

体裁

PDF / 230ページ

販売価格

2,400USD

発行

Azoth Analytics

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE